NRXPWNRX Pharmaceuticals Inc. Warrant
Data unavailable—Mkt Cap: —P/E: —124d ago
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), an…
Industry Peers
Biotechnology$133.74BUSDP/E 30.8
$78.76BUSD
$77.45BUSDP/E 18.6
$60.46BUSDP/E 37.0
$57.09BUSDP/E 36.6
$44.04BUSDP/E 18.8
$43.24BUSD
$41.52BUSDP/E 65.7
$34.17BUSDP/E 44.6
$33.73BUSDP/E 31.4
$26.71BUSD
$25.70BUSD
$25.30BUSDP/E 15.9
$24.89BUSD
$21.74BUSDP/E 28.1
$20.62BUSDP/E 27.7
$15.47BUSDP/E 16.3
$15.13BUSDP/E 18.1
$14.46BUSDP/E 18.4
$13.02BUSD
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)2.29M $
Gross Profit720.00K $
Net Income (TTM)-28.62M $
Revenue/Share0.0900 USD
Last Price—
Fiscal Year End—
MR Quarter—
Employees29
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.01
EPS (TTM)-6.25
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin58.78%
Oper. Margin-444.57%
EBITDA Margin0.00%
Profit Margin-2336.49%
ROE179.59%
ROA-220.92%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-14.11M $
CapEx (TTM)—
FCF Margin-372.53%
FCF Yield—
Net Debt-5.78M $
Net Debt/EBITDA0.34
Balance Sheet
Debt/Equity-0.04
Current Ratio0.29
Quick Ratio0.27
Book Value/Sh-0.4130 USD
Cash/Share0.1850 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float30.45M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta2.02
S&P 52W Chg15.96%
Avg Vol (30d)—
Avg Vol (10d)—
Technical Indicators
RSI (14)9.2
MACD-0.0003
MACD Signal-0.0005
MACD Hist.+0.0001
BB Upper0.0142 USD
BB Middle0.0142 USD
BB Lower0.0142 USD
BB Width0.00%
ATR (14)0.0001 USD
Vol Ratio (20d)—